1093.HK in “China Becomes Pharma's Global R&D Engine”
CSPC Pharmaceutical Group Limited
CSPC combines a large Chinese commercial base with an innovative pipeline whose antibodies, ADCs and metabolic programs offer multiple opportunities for international licensing.
1093.HK impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 1093.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 1093.HK impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 212 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — CSPC combines a large Chinese commercial base with an innovative pipeline whose antibodies, ADCs and metabolic programs offer multiple opportunities for international licensing.
Read the full China Becomes Pharma's Global R&D Engine story